# Heinz-Josef Lenz

Source: https://onco.cc/people/heinz-josef-lenz/  
OnCo record `heinz-josef-lenz` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Colorectal oncologist who led CheckMate 142 and co-led CheckMate 8HW, bringing nivolumab plus ipilimumab to MSI-high disease.

## Summary

Heinz-Josef Lenz was a lead investigator of CheckMate 142 and CheckMate 8HW, which established nivolumab plus ipilimumab in MSI-high colorectal cancer, and led the analyses of CALGB/SWOG 80405 showing that primary tumour side predicts benefit from anti-EGFR therapy. He has long studied pharmacogenomics of fluoropyrimidines and leads SWOG GI trials.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: colorectal; immunotherapy; swog
- Role: Professor of Medicine and Co-Director, Colorectal Center, USC Norris Comprehensive Cancer Center
- Specialisms: Colorectal cancer; Immunotherapy; Pharmacogenomics; Tumour sidedness

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Lenz%20HJ%5BAuthor%5D%20colorectal%20nivolumab

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [CTLA-4](https://onco.cc/targets/ctla4/), [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- institutions: [USC Norris Comprehensive Cancer Center](https://onco.cc/institutions/usc-norris/)
- trials: [CheckMate 8HW](https://onco.cc/trials/checkmate-8hw/)
- key papers: [Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial](https://onco.cc/key-papers/paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024/), [Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in KRAS wild-type advanced or metastatic colorectal cancer (CALGB/SWOG 80405)](https://onco.cc/key-papers/paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017/), [Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405](https://onco.cc/key-papers/paper-lenz-cms-calgb-swog-80405-jco-2019/), [Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer (CheckMate 8HW)](https://onco.cc/key-papers/paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024/), [Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials](https://onco.cc/key-papers/paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017/), [Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials](https://onco.cc/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/), [Randomized trial of TAS-102 for refractory metastatic colorectal cancer (RECOURSE)](https://onco.cc/key-papers/paper-mayer-recourse-tas-102-nejm-2015/), [Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT)](https://onco.cc/key-papers/paper-grothey-correct-regorafenib-lancet-2013/)

---
JSON: https://onco.cc/api/v1/entities/heinz-josef-lenz.json